Pharmacogenomics of tamoxifen and irinotecan therapies.

[1]  S. Hirohashi,et al.  Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients. , 2008, Cancer letters.

[2]  P. Houghton,et al.  An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11 , 2008, Cancer Gene Therapy.

[3]  M. Bally,et al.  Irinophore C: A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy against a Panel of Human Xenograft Tumors , 2008, Clinical Cancer Research.

[4]  M. Goetz,et al.  Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response , 2008, Clinical pharmacology and therapeutics.

[5]  M. Ingelman-Sundberg,et al.  Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, Pharmacology & therapeutics.

[6]  E. Bandrés,et al.  Combining chemotherapy and targeted therapies in metastatic colorectal cancer. , 2007, World journal of gastroenterology.

[7]  Wolfgang Simon,et al.  Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Soma Das,et al.  Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Joseph G Ibrahim,et al.  UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. , 2007, Journal of the National Cancer Institute.

[10]  J. Panetta,et al.  UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Linnea M Baudhuin,et al.  Comparison of three methods for genotyping the UGT1A1 (TA)n repeat polymorphism. , 2007, Clinical biochemistry.

[12]  Tae Won Kim,et al.  Insights, Challenges, and Future Directions in Irinogenetics , 2007, Therapeutic drug monitoring.

[13]  Y. Hasegawa,et al.  UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy. , 2007, Current opinion in molecular therapeutics.

[14]  M. Narabayashi,et al.  Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer , 2007, Cancer Chemotherapy and Pharmacology.

[15]  Q. Pan,et al.  Validation of Rapid Polymerase Chain Reaction-based Detection of All Length Polymorphisms in the UGT 1A1 Gene Promoter , 2007, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[16]  S. Wingren,et al.  Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer , 2007, Breast Cancer Research.

[17]  M. Ratain,et al.  The Role of SN‐38 Exposure, UGT1A1*28 Polymorphism, and Baseline Bilirubin Level in Predicting Severe Irinotecan Toxicity , 2007, Journal of clinical pharmacology.

[18]  M. Ratain,et al.  Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. , 2006, Pharmacogenomics.

[19]  W. Burke,et al.  Adding pharmacogenetics information to drug labels: lessons learned , 2006, Pharmacogenetics and genomics.

[20]  D. Young.  Genetics examined in tamoxifen's effectiveness: recurrence warning urged for labeling. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[21]  M. Narabayashi,et al.  Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN‐38 glucuronidation in Japanese patients with cancer , 2006, Cancer science.

[22]  T. Bevers.  Raloxifene and the prevention of breast cancer , 2006, Expert opinion on pharmacotherapy.

[23]  S. Loibl,et al.  Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  P. O'dwyer,et al.  Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  B. Bonanni,et al.  Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Zeruesenay Desta,et al.  Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment , 2006, Clinical pharmacology and therapeutics.

[27]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[28]  M. Ratain,et al.  Irinogenetics: what is the right star? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Gelber,et al.  Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Remmel,et al.  Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer , 2006, Oncogene.

[31]  Fergus J Couch,et al.  Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Thomas J. Smith,et al.  Review: chemotherapy and hormonal therapy reduce recurrence and mortality at 15 years in early breast cancer , 2005, ACP journal club.

[33]  J. Scheys,et al.  Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients , 2005, Breast Cancer Research and Treatment.

[34]  G. Wilkinson,et al.  Drug metabolism and variability among patients in drug response. , 2005, The New England journal of medicine.

[35]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[36]  N. Meropol,et al.  UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  T. Skaar,et al.  Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen , 2005, Cancer Chemotherapy and Pharmacology.

[38]  L. Skoog,et al.  Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients , 2005, Breast Cancer Research.

[39]  J. Flaws,et al.  Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. , 2005, Cancer letters.

[40]  David A. Flockhart,et al.  CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.

[41]  J. Cuzick,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[42]  David A. Flockhart,et al.  Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[43]  J. Verweij,et al.  Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN‐38 , 2004, Journal of clinical pharmacology.

[44]  J. Verweij,et al.  Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38 , 2004 .

[45]  T. Skaar,et al.  Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen , 2004, Breast Cancer Research and Treatment.

[46]  Soma Das,et al.  Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  J. Watters,et al.  Irinotecan pharmacogenetics: is it time to intervene? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Jeffrey Cummings,et al.  Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. , 2003, Cancer research.

[49]  C. Guillemette,et al.  Novel Functional Polymorphisms in the UGT1A7 and UGT1A9 Glucuronidating Enzymes in Caucasian and African-American Subjects and Their Impact on the Metabolism of 7-Ethyl-10-hydroxycamptothecin and Flavopiridol Anticancer Drugs , 2003, Journal of Pharmacology and Experimental Therapeutics.

[50]  V. Stearns,et al.  Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. , 2003, JAMA.

[51]  M. Ingelman-Sundberg,et al.  Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[52]  Guangping Chen,et al.  4‐Hydroxytamoxifen sulfation metabolism , 2002, Journal of biochemical and molecular toxicology.

[53]  L. Hutchins,et al.  Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. , 2002, Journal of the National Cancer Institute.

[54]  J. Brockmöller,et al.  Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[55]  C. Guillemette,et al.  Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). , 2002, Molecular pharmacology.

[56]  M. Eichelbaum,et al.  The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. , 2002, British journal of clinical pharmacology.

[57]  E. Gillam,et al.  Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[58]  M. Ando,et al.  Genetic Polymorphisms of the UDP‐Glucuronosyltransferase 1A7 Gene and Irinotecan Toxicity in Japanese Cancer Patients , 2002, Japanese journal of cancer research : Gann.

[59]  S. Ozawa,et al.  Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[60]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[61]  Osborne Ck,et al.  Tamoxifen in the Treatment of Breast Cancer , 1998 .

[62]  S. Lundgren,et al.  Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. , 1989, Cancer research.

[63]  H. Rochefort,et al.  Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. , 1981, The Journal of biological chemistry.

[64]  V. Jordan,et al.  A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. , 1977, The Journal of endocrinology.

[65]  S. Lundgren,et al.  Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[66]  David A. Flockhart,et al.  The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen , 2006, Breast Cancer Research and Treatment.

[67]  Yoshiro Saito,et al.  Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[68]  H. Rochefort,et al.  Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. , 1982, Cancer research.

[69]  B. Katzenellenbogen,et al.  Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. , 1982, Journal of steroid biochemistry.